Replies to post #88660 on Biotech Values

[DewDiligence]

Boosting in this case isn't simply about QD vs. BID, there is clinical evidence that the resistance barrier is compromised if the PI regimen is not boosted.

I’ve never heard such a claim. If this is true, why does the FDA label for Reyataz include both boosted and non-boosted dosing options?